Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Charles River Laboratories International $1 billion senior notes offering
We advised Charles River Laboratories on the high-yield debt offering
Solid Biosciences $143.75 million follow-on equity offering
We advised the joint book-running managers on the stock offering
Connect Biopharma $219.9 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Anthem $3.5 billion senior notes offering
We advised the underwriters on the investment-grade debt offering
Illumina $1 billion notes offering
We advised the underwriters on the investment-grade debt offering
MediaAlpha $370.3 million secondary offering
We advised the underwriters on the SEC-registered stock offering
Oncopeptides SEK 1.1 billion private placing of new shares
We advised Oncopeptides on the private placement of shares
Oak Street Health $920 million convertible senior notes offering
We advised the initial purchasers on the Rule 144A offering
Prometheus Biosciences $218.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Avid Bioservices $143.8 million exchangeable senior notes offering
We advised the initial purchasers on the Rule 144A offering